may, 2015

18mayallday20alldayBioconjugates: From Targets to Therapeutics


Event Details

This is the first and only conference to focus on bioconjugation techniques from a holistic standpoint. Going beyond just ADCs, to look at the latest research and innovations across all topics within bioconjugates including ADCs, bispecific conjugations, nanoparticle conjugations and more.


Complete Brochure Now Available
» Download Today!

\’It was a pleasure presenting at the Bioconjugates conference in June 2014. The presentations and discussion were very stimulating and there was excellent new information.\’ – Philip Howard, Ph.D., Chief Scientific Officer, Spirogen, United Kingdom

By Attending You Will:

  • Gain insights on novel payloads, new linkers and alternative binding modalities, and updates on the latest in ADC discovery and development
  • Hear Seattle Genetics and Genentech present their strategies for overcoming CMC and regulatory challenges
  • Learn from advances beyond ADCs, including bispecific conjugations, nanoparticle conjugations and more

\’Great variety of bioconjugation modalities. I\’m sure this sort of crosstalk will create new innovations.\’ – Roger Pak, Pfizer

Keynote Presentations

\'PeterPotent Antibody Drug Conjugates for Cancer Therapy
Peter Senter, Ph.D.
Vice President, Chemistry
Seattle Genetics

\'PaulBispecific Antibodies – Are We There Yet?
Paul J. Carter, Ph.D.
Staff Scientist and Senior Director, Antibody Engineering
Genentech, Inc.

\'AndreasNew Engineering and Application Perspectives of Scaffold Proteins
Andreas Plückthun, Ph.D.
Director, Department of Biochemistry
University of Zurich, Switzerland

\'PatrickDevelopment of Bite® Antibody Construct Blinatumomab – The First FDA-Approved Bispecific Antibody
Patrick Baeuerle
Vice President, Research; General Manager
Amgen Research GmbH, Germany

\'JamesEngineered Proteins for Signaling
Jim Wells, Ph.D.
Professor and Chair, Pharmaceutical Chemistry

\'MarkReceptor-Mediated Delivery of Bispecific Antibodies into the Primate Brain: Challenges and Safety Findings
Mark Dennis, Ph.D.
Principal Scientist, Antibody Engineering
Genentech, Inc.

\’A great conference with all the experienced scientists involved in ADC therapeutics – \’one-and-only shop for ADCs\’ – great location too.\’ – Ananda Senevir, Agensys


may 18 (Monday) - 20 (Wednesday)


Parc 55 Hilton

San Francisco, California